We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current PVLA market cap is 27.33M. The company's latest EPS is USD -55.0029 and P/E is -0.38.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 746k | 3.44M | 2.72M | 1.06M | 761k |
| Operating Income | -37.06M | -7.35M | -5.87M | -7.3M | -6.48M |
| Net Income | -36.48M | -7.23M | -5.32M | -7.1M | -52.97M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 5.08M | 14.57M | 6.15M | 7.98M |
| Operating Income | -1,000 | -80.99M | -177.04M | -120.96M | -26.92M |
| Net Income | -1,000 | -81.51M | -157.13M | -115.59M | -72.62M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 60.43M | 50.4M | 45.11M | 38.74M | 56.25M |
| Total Liabilities | 19.52M | 16.2M | 15.3M | 15.32M | 65.79M |
| Total Equity | 40.91M | 34.2M | 29.81M | 23.42M | -9.53M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 137k | 235.82M | 167.63M | 60.43M | 56.25M |
| Total Liabilities | 113k | 21.86M | 23.18M | 19.52M | 65.79M |
| Total Equity | 24k | 213.96M | 144.45M | 40.91M | -9.53M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -76.62M | -7.24M | -13.03M | -17.53M | -22.63M |
| Investing | 64.68M | 15.94M | 15.8M | 15.78M | 6.88M |
| Financing | -82k | -43k | -70k | -63k | 23.8M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | N/A | -42.1M | -65.39M | -76.62M | -22.63M |
| Investing | N/A | -4.69M | -109.05M | 64.68M | 6.88M |
| Financing | N/A | 230.24M | -7.52M | -82k | 23.8M |
| Market Cap | 27.33M |
| Price to Earnings Ratio | -0.38 |
| Price to Sales Ratio | 3.44 |
| Price to Cash Ratio | 0.88 |
| Price to Book Ratio | -2.88 |
| Dividend Yield | - |
| Shares Outstanding | 1.32M |
| Average Volume (1 week) | 25.53k |
| Average Volume (1 Month) | 51.85k |
| 52 Week Change | 66.94% |
| 52 Week High | 21.71 |
| 52 Week Low | 11.10 |
| Spread (Intraday) | 5.17 (21.26%) |
| Company Name | Palvella Therapeutics Inc |
| Address |
108 w. 13th street suite 100 wilmington, delaware 19801 |
| Website | https://www.sarcos.com |
| Industry | blank checks (6770) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
